Second-line chimeric antigen receptor T-cell therapy versus standard of care in relapsed or refractory large B-cell lymphoma: A systematic review and meta-analysis

Researchers conducted a systematic review and meta-analysis of data from 1,199 patients from three randomized controlled trials (ZUMA-7, TRANSFORM, and BELINDA) and one real-world comparative study evaluating second-line CAR-T versus standard-of-care chemoimmunotherapy in adults with early relapsed/refractory large B-cell lymphoma. They found that second-line CAR T-cell therapy significantly improved long-term survival and disease control in this patient population, and these benefits were seen across subgroups as well as in real-world settings.